EDUCATION & ACADEMIC TITLES

May 2000: Degree in Medicine by the Medical School of Justus-Liebig University in Giessen, Germany

March 2010: Board certification in Hematology

December 2014: Dissertation by the Medical School of National and Capodistrian University of Athens, Greece: Study of the prognostic impact of serum free light chain ratio in patients with multiple myeloma. Investigation of biological mechanisms regulating secretion of free light chains by neoplasmatic plasma cells

PROFESSIONAL EXPERIENCE

• 7/2000 – 1/2002 Residency in Internal Medicine Klinikum Offenbach, Germany
• 3/2004 – 3/2005 Obligatory Service as General Practicioner
• 5/2005 – 11/2005 Residency in Internal Medicine in the Hospital for special diseases in Thessaloniki, Greece
• 11/2005 – 11/2009 Fellowship in Hematology in “Metaxa” hospital in Piraeus
• 7/2010 – 2/2011 Hematologist, Tzaneio Hospital, Piraeus, Greece
• 2/2011 – 12/2014 Hematologist, Florina General hospital, Greece
• 1/2015 – 5/2015 Hematologist in the clinic for Hematology and Oncology of Marienhospital, Düsseldorf, Germany
• 10/2015 – 5/2018 Hematologist, 1st Propedeutic Clinic for Internal Medicine, Laikon General Hospital, Athens, Greece
• 6/2018 – 7/2022 Hematologist in “Metaxa” hospital in Piraeus
• Since 8/2022 Hematologist in Metropolitan Hospital

MEMBERSHIP IN SOCIETIES & EDITORIAL BOARDS

• Member of Medical Association of Piraeus
• Member of Hellenic Hematology Association
• Member of European Hematology Association
• Reviewer for the scientific Magazine “Case reports in Hematology”

RESEARCH PROGRAMS

• Subinvestigator in MiraCLLe Study: An Epidemiological, Prospective, two-year cohort study to Record the True First- and Second-Line Treatment Strategy, in Daily Clinical Practice, Metropolitan Hospital

DISTINCTIONS & AWARDS

• “Young Investigator Award” for the following oral presentation in the Sixth International Workshop on Waldenstrom’s Macroglobulinemia, October 6 – 10 2010, Venice, Italy.
  Clinical impact of increased serum free light chains (sFLCs) or their ratio (FLCR) on WM at diagnosis and during disease course.
  D. Maltezas, T. Tzenou, N. Kafassi, E. Koulieris, V. Bartzis, M. Dimou, A. Efthymiou, G. Georgiou, T.P. Vassilakopoulos, M.K. Angelopoulou, P. Tsaftaridis, P. Panayiotidis, P. Beris, M-C Kyrtsonis.
  Quantification of serum IgM kappa and IgM lambda in patients with Waldenstrom’s Macroglobulinemia.
  E. Koulieris, M-C Kyrtsonis, D. Maltezas, T. Tzenou, L. Mirbahai, G. Mead, P. Panayiotidis, A.R. Bradwell, S. Harding.
• Award for best Poster in its category. 7TH International Symposium on Clinical Applications of FLC & HLC, Edinburgh, UK, 16-17/6/15 για την εργασία:
  Serum free light chain (FLC) and soluble syndecan-1 levels are major markers of disease evolution of smoldering multiple myeloma (SMM) patients.
  Nikolaou E, Maltezas D, Koulieris E, Iliakis T, Viniou NA, Kotsanti S, Bitsani A, Bartzis V, Tzenou T, Dimou M, Panayiotidis P, Kyrtsonis MC.
  Hematology Reports 2015; 7(s1), pp28

PUBLICATIONS

• Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.
  Maltezas D, Dimopoulos MA, Katodritou I, Repousis P, Pouli A, Terpos E, P, Delimpasi S, Michalis E, Anargyrou K,Gavriatopoulou M, Stefanoudaki A, Tzenou T, Koulieris E, Sachanas S, Dimou M, Vassilakopoulos TP, Angelopoulou MK, Pangalis GA, MC. Hematol Oncol. 2012
• Prognostic significance of serum free light chains in Chronic Lymphocytic Leukemia
  K. Sarris, D. Maltezas, E. Koulieris, V. Bartzis, T. Tzenou, S. Sachanas, E. Nikolaou, A. Efthymiou, K. Bitsani, M. Dimou, T. Vassilakopoulos, M. Siakantaris, M. Angelopoulou, F. Kontopidou, P. Tsaftaridis, N. Kafasi, G. Pangalis, P. Panayiotidis, S. Harding, M-C. Kyrtsonis.
  Adv Hematol. 2013;2013:359071
• Contribution of new immunoglobulin-derived biomarkers in plasma cell dyscrasias and lymphoproliferative disorders.
  Kyrtsonis MC, Maltezas D, Koulieris E, Tzenou T, Harding SJ.
  WorldJHematol 2013; 2(2): 6-12
• The contribution of prognostic factors to the better management of multiple myeloma patients.
  M-C Kyrtsonis, D Maltezas, E Koulieris, Catherine Bitsanis, Ilias Pessach, Anna Efthymiou, Vassiliki Bartzis, Tatiana Tzenou, Panayiotis Panayiotidis.
  Multiple Myeloma An Overview Chapter 8: Pages 145-174
• Response to bortezomib in refractory/relapsed multiple myeloma patients: a single center experience with discussion on specific issues.
  M-C. Kyrtsonis, D. Maltezas, E. Koulieris, C. Zaroulis, T. Tzenou, S. Sachanas, V. Bartzis, G. Georgiou, M. Dimou, S. Siakavellas, T.P. Vassilakopoulos, M.K. Angelopoulou, E. Koutra, A. Mouzaki, G.A. Pangalis, P. Panayiotidis.
  The Asia-Pacific Journal of Oncology & Hematology 2010; Vol 1, Issue 4
• Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.
  M-C. Kyrtsonis, D. Maltezas, T. Tzenou, E. Koulieris, A.R. Bradwell.
  Seminars in Hematology. 2009 (2):110-7
• Aberrant Immunoglobulin Variations as Indicators of Eventual Clonal Changes in Symptomatic Multiple Myeloma Patients' Course.
  Nikolaou E, Koulieris E, Maltezas D, Sarris A, Iliakis T, Vyniou N.A, Vardounioti I, Κarali V, Pessah I, Efthymiou A, Bitsani A, Bartzis V, Tzenou T, Dimou M, Vassilakopoulos TP, Angelopoulou ΜΚ, Tsaftaridis P, Tsalimalma K, Κafasi Ν, Panayiotidis P, Kyrtsonis M-C.
  CurrentCancerTherapyReviews, 2014, 10.2: 90-96
• Biology and treatment of skeletal manifestations in multiple myeloma
  Stavropoulos N, Papadoyiannis A, Maltezas D, Stavrou P, Pangalis GA, Papagelopoulos PJ, Kyrtsonis MC.
  Journal of Cancer Therapy, 2014, 5, 387-402.
• Prognostic contribution of new immunoglobulin biomarkers (Freelite, Hevylite) in Waldenstrom’s Macroglobulinemia (WM).
  MC Kyrtsonis, E. Koulieris, D. Maltezas, T. Tzenou, S. Harding, E. Kastritis, N. Kafassi, V. Bartzi, A. Efthymiou, K. Bitsanis, M. Gavriatopoulou, E. Terpos, C. Kalpadakis, M K Angelopoulou, T. P. Vassilakopoulos, AR Bradwell, PH. Berris, GA Pangalis, P. Panayiotidis, MA Dimopoulos
  American Journal of Medicine and Medical Science 2012; 2(6): 136-143
• Novel m-component based biomarkers in Waldenström’s Macroglobulinemia.
  Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S, Dulery R, Boyle E, Gauthier J, Poulain S, Tatiana T, Panayiotidis P, Bradwell AR, Harding S, Leblond V, Kyrtsonis MC, Ghobrial IM Clin Lymphoma Myeloma Leuk. 2011;11(1):164-7

CONTACT INFO

+30 210 4809471

PROFFESSIONAL HISTORY

• Feb 2020 - today: Associate director of the 2nd Haematology clinic, Metropolitan Hospital, Piraeus
• 2019: “Excellence in thrombosis” certification by the “institute for studying & educating about thrombosis and antithrombotic treatment”
• 2017 - today: Volunteer haematologist in Ag.Stefanos’ social clinic.
• 2015 - today: Reviewer for “Blood coagulation and fibrinolysis” journal
• May 2013 - Jan 2020: Haematology consultant for Mediterraneo Hospital, Glyfada, Greece. In charge of haemostasis department/outpatient clinic
• May 2013 - today: Collaborating with the haemostasis group of “Tenon” university hospital, Paris, France in patient management, studies, congress presentations etc.
• 2011 - 2012: “Stage de perfectionnement” in haemostasis as an intern, at the “Service d’ Hematologie biologique”, Tenon Hospital Paris (Université Pierre et Marie Curie, Paris VI), France
• 2010 - 2013: Registrar MD specialising in Haematology in the Haematology Clinic of “Metaxa” Specialised Anti-Cancer Hospital of Piraeus
• 2008  - 2010: Registrar MD specialising in Haematology in the Haematologic department and the Transfusion Centre of “Aghios Panteleimon” General Hospital of Nikea, Piraeus
• 2008 - 2008: Volunteer External Scientific Partner for the Haematology clinic of the “Amalia Fleming” General Hospital of Melissia
• 2006 - 2008: Registrar MD specialising in Internal Medicine in the 1st Internal Medicine Clinic of the “Amalia Fleming” General Hospital of Melissia.
• 2005 - 2006: SHO residency in internal medicine, general surgery and cardiology at Thebes General Hospital in preparation of the rural medical service and Rural Medical Service at the regional medical station of Pili of Schimatari’s health centre of Thiva’s General Hospital

EDUCATION

• 2001 - today Presence in medical seminars & congresses
• 2008 Issued a Licence to teach English in foreign language schools, by the Secondary Education Office
• 2003 Recognition of Medical Degree by the Interuniversitary Centre for Recognising Foreign Study Diplomas (DI.K.A.T.S.A) after successfully taking exams in the fields of Internal Medicine & Surgery
• 2001: Medical Degree from the University of Medicine and Pharmacy “Gr. T. Popa”, Iasi-Romania (English language department)
• 1995: Highschool Diploma by the General Highschool of Drossia
• 1994: Awarded the “Cambridge Certificate Of Proficiency In English”

SPOKEN LANGUAGES

• Greek: Fluent (native)
• English: Fluent
• Romanian: Fluent
• French: Limited working proficiency

SCIENTIFIC WORK

• 8th Educational Vascular Conference “Prevention - Treatment - Complications of Thromboembolic Disease in the 21st Century” Athens, January 25th 2020, Grand Amphitheater of “Sotiria” hospital, Athens, Greece
• 7th Interactive Educational Vascular Conference “Venous Thromboembolic Disease versus Effective Treatment. Are you ready?" Athens, 19th of January 2019, Grand Amphitheater of “Sotiria” hospital, Athens, Greece
• Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer - Associated Thrombosis: The Observational ROADMAP - CAT Study. Oncologist. 2018 Aug 13. pii: theoncologist.2017-0530. doi: 10.1634/theoncologist.2017-0530. [Epub ahead of print]
  Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, Elalamy I, Falanga A, Gerotziafas GT.
• 3rd educational symposium of the 1st ICU Clinic of Athens’ university of medicine. Dealing with Respiratory Problems in the Community: Thrombophilia testing after thromboembolic event and the effect of its results on treatment. May 18th-19th 2018, Athens, Greece, Doma Amphitheater, "Evangelismos" general hospital
• 5th Winter School of Thrombosis - Antithrombotic Education: Understanding the Data of Clinical Studies and Their Impact on Clinical Practice: Co-administration of Antiplatelets and DOACs. Latest data
• 5th Panhellenic Conference on Thrombosis - Antithrombotic Education: Facts and gaps in the treatment of thromboembolic venous disease in patients with multiple myeloma. September 21st-23rd, 2017, Egli Zappeiou, Athens, Greece
• ANCA-Negative Churg-Strauss Syndrome Presenting as Acute Multiple Cerebral Infarcts: A Case Report. Journal of Stroke and Cerebrovascular diseases
  Klearchos Psychogios, MD1, Ilias Evmorfiadis, MD2, Spyros Dragomanovits, MD3, Athanasios Stavridis, MD1, Konstantinos Takis, MD1, Loukas Kaklamanis, MD4, and Stathis Pantelis, MD1
• 5th Educational Angiology day conference, grand amphitheater “Sotiria” Hospital 19/11/2016: VTE Treatment in Thrombophilia (Oral presentation)
• American Society of Clinical Oncology annual meet.ing, June 3-7 2016, Chicago, Illinois: Identification of clinical variables and biomarkers of hypercoagulability for VTE risk evaluation in ambulatory patients with lung adenocarcinoma on chemotherapy: The ROADMAP study
  Grigoris Gerotziafas, Paraskey Boura, Andriani Charpidou, Ioannis Gkiozos, Ilias Evmorfiadis, Patrick Van Dreden, Aurelie Rousseau, Rabiatou Sangare, Annette K Larsen, Konstantinos N. Syrigos, Ismail Elalamy
• American Society of Clinical Oncology annual meeting, June 3-7 2016, Chicago, Illinois: A clinico-biological Risk Assessment Model for VTE in ambulatory patients with lung adenocarcinoma on chemotherapy issued from the ROADMAP study
  Grigoris Gerotziafas, Ilias Evmorfiadis, Paraskevi Boura, Patrick Van Dreden, Andriani Charpidou, Aurelie Rousseau, Annette K Larsen, Konstantinos N. Syrigos, Rabiatou Sangare, Ioannis Gkiozos, Ismail Elalamy
• 2016 ISTH SSC, Montpellier France, May 25-28: Biomarkers of hypercoagulability and clinical variable related with VTE risk in ambulatory patients with lung adenocarcinoma on chemotherapy. The ROADMAP study
  Gerotziafas G1,2, Evmorfiadis I1, Boura P3, Rousseau A4, Charpidou A3, Van Dreden P4, Giozos G3, Grusse M4, Sangate R2, Larsen A2, Syrigos K3 and Elalamy I1,2
• 2016 ISTH SSC, Montpellier France, May 25-28: Development of a new risk assessment model for VTE specific for ambulatory patients with lung adenocarcinoma on chemotherapy. The ROADMAP study
  Gerotziafas G1,2, Evmorfiadis I3, Van Dreden P4, Boura P5, Rousseau A4, Charpidou A5, Giozos G5, Grusse M4, Larsen A2, Sangare R2, Syrigos K5 and Elalamy I1,2
• Biennial International Congress on Thrombosis, Istanbul, Turkey - May 4-7, 2016: A NEW RISK ASSESSMENT MODEL FOR VTE IN AMBULATORY PATIENTS WITH LUNG ADENOCARCINOMA ON CHEMOTHERAPY. THE ROADMAP STUDY
  Gerotziafas G, Evmorfiadis I, Boura P, Giozos G, Charpidou A, Rousseau
  A, Van Dreden P, Grusse M, Annette Larsen, Syrigos K, Ismail Elalamy
• Biennial International Congress on Thrombosis, Istanbul, Turkey - May 4-7, 2016: SELECTION OF BIOLOGICAL MARKERS OF HYPERCOAGULABILITY FOR THE IDENTIFICATION OF HIGH VTE RISK PATIENTS WITH LUNG ADENOCARCINOMA. THE ROADMAP STUDY
  I. Evmorfiadis, P. Boura, A. Rousseau, A. Charpidou, G. Giozos, P. Van
  Dreden, K. Syrigos, A. Larsen, Ismail Elalamy, G. T. Gerotziafas
• 8th ICTHIC, April 8-10, 2016 Bergamo, Italy: Prospective evaluation of risk assessment models and biological markers of hypercoagu-lability for the identification of high VTE risk patients with lung adenocarcinoma. The ROADMAP study Thromb Res.
  2016 Apr;140 Suppl 1:S196. doi: 10.1016/S0049-3848(16)30186-4. Epub 2016 Apr 8.
  P. Boura, I. Evmorfiadis, A. Rousseau, A. Charpidou, G. Giozos, P. Van Dreden, K. Syrigos, A. Larsen, I. Elalamy, G. T. Gerotziafas (Greece, France)
• ISTH 2015 Congress, Toronto, June 20-25: Prospective Evaluation of Risk Assessment Models and Biological Markers of Hypercoagulability for the Identification of High VTE Risk Patients With Lung Adenocarcinoma. The ROADMAP Study.
  Ilias Evmorfiadis1,2,5, Paraskevi Boura3, Aurélie Rousseau1,2,4, Ariadni Charpidou2, Giannis Giozos2, Patrick Van Dreden4, Konstantinos Syrigos2, Anastasia Spanoudaki5, Matthieu Grusse4, Ismail Elalamy 1,2 and Grigoris T. Gerotziafas1,2
  
  56th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA, 6-9 December 2014: Differential Influence of Lung Cancer Stage, Time from Diagnosis and Chemotherapy on Plasma and Cellular Biomarkers of Hypercoagulability. The ROADMAP Study
  Ilias Evmorfiadis1, Paraskevi Boura2, Aurélie Rousseau3,1, Ariadni Charpidou2, Giannis Giozos2, Patrick Van Dreden, PhD4, Konstantinos Syrigos2, Anastasia Spanoudaki5, Matthieu Grusse3, Ismail Elalamy, MD6,5, and Grigorios T. Gerotziafas7,5
• 55th American Society of Hematology Annual Meeting and Exposition, New Orleans 7-10 December 2013: A Synthetic Evaluation Of Genetic and Pharmacological Resistance To Clopidogrel and On Treatment Residual Platelet Aggregation In Patients With Atherothrombosis
  Grigoris T Gerotziafas1,2*, Severin Bouffard3*, Patrick Van Dreden, Ph.D.4, Amir Kartechi5*, Ilias Evmorfiadis6*, Marie-Paule Roman3*, Vassiliki Galea3,6*, Dimitra Karipidi6* and Ismail Elalamy, MD7,8*
• 2nd Educational Workshop in Angiology, November 16, 2013, Grand Amphitheatre of "Sotiria" hospital, Athens
  Thrombophilia treatment
  Ilias Evmorfiadis, Gregory Gerotziafas
• 8th International Congress on Vascular Dementia & The First Cognitive Impairment European Meeting, Athens, Greece, October 17-20, 2013
  Anticoagulant & Antiplatelet Treatment in Dementia Patients, a puzzling question
  I.Evmorfiadis1, N.G. Tsamopoulos2, G.T. Gerotziafas3
• Publication on «Haema» October – December 2011, Vol. 2-Issue 4, notices for publication:
  Massive lymphadenopathy due to Castleman’s disease: Four case-presentations
  I. Evmorfiadis1, I. Patsias1, Α. Konstantinou1, Μ. Plega1, Μ. Stamouli1, Κ. Galani2, Κ. Ntatsis3, Ι. Iakovidou2, E. Megalakaki1
• Publication on «Haema» – December 2011, Vol. 2-Issue 4, notices for publication:
  Immunoglobulin levels and infections in Multiple Myeloma patients, on two different Bortezomib-based chemotherapeutic groups
  Α. Konstantinou1, Μ. Stamouli1, I. Evmorfiadis1, I. Patsias1, V. Chatziantoniou1, Μ. Dadakaridou1, Ν. Tragomallos3, Μ. Aslanidou2, Ε. Sotiropoulou2, Μ. Kotsopoulou1, P. Repousis1, E. Megalakaki1
• Letter to the editor, journal of Balkan Union of Oncology:
  “Castleman disease and adenocarcinoma” vol. 16, no. 4, 2011, pp 781-782, issue of J BUON
  A. Megalakaki1, I. Evmorfiadis1, M. Stamouli1, N. Zakopoulou2, I. Iacovidou3
• Internal Medicine Days 2011, Athens, 15-16 April 2011:
  New flu caused by H1N1: Clinical features in patients with haematologic diseases
  E.Konstantinou1, Μ.Stamouli1, F.Katis1, G.Papageorgiou1, I.Evmorfiadis1, E.Lamprou2, V.Papaemmanouil2, Μ.Kotsopoulou1, P.Repousis1, E.Megalakaki1
• 21st Hellenic Haematology Congress, Thessaloniki, 10-12 November 2010:
  DEFINING THE ACTIVITY OF MICROVESICLES IN PATIENTS WITH Ph(-) MYELOPROLIFERATIVE NEOPLASIAS
  I. Patsias1, I. Evmorfiadis1, E. Kalagiakou1, A. Tsiampouris1, E. Samaridis1, G. Papadopoulos2, E. Kalouda1, L. Fountoulaki2, E. Manioudaki1, N. Laoutaris1
• 21st Hellenic Haematology Congress, Thessaloniki, 10-12 November 2010:
  PLATELET FUNCTION STUDY IN PATIENTS WITH Ph(-) MYELOPROLIFERATIVE NEOPLASIAS. CORRELATION WITH THE MUTATED JAK-2 COPIES LOAD AND THE PRESENCE OF THROMBOTIC EPISODES
  E. Kalagiakou1, I. Evmorfiadis1, A. Tsiambouris1, M. Chatzouli1, I. Patsias1, K. Vallianatou1, E. Sotiropoulou2, A. Zefkilis1, C Belessi1, L. Fountoulaki2, N. Laoutaris1, E. Manioudaki1
• 6th Hellenic Transfusion Therapy Congress, Ioannina 22-24 April 2010
  CHARACTERISTICS OF REPLACEMENT BLOOD DONORS
  Sotiropoulou E., Evmorfiadis I., Papadopoulos G., Fakitsa V., Stamoulis K., Fountoulaki-Paparizou L.
  Transfusion Centre of G.H. of Nikea-Piraeus “Ag.Panteleimon”
• 14th EHA Congress, June 4-7 2009, Berlin, Germany:
  JAK2 V617 ALLELE BURDEN AND THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
  E. Kalagiakou ,I. Evmorfiadis ,M. Hatzouli ,E. Manioudaki ,M. Kotsopoulou ,S. Malegkou ,K. Vallianatou ,I-D. Triantafyllopoulou ,E. Samaridis ,L. Dadiotis ,Ch. Mitsouli ,C. Belessi ,N. Laoutaris
• 19th Hellenic Haematology Congress, Athens 19-22 November 2008
  TREATING del 5q MYELODYSPLASTIC SYNDROMES WITH LOW DOSE LENALIDOMIDE
  E. Manioudaki1, I. Evmorfiadis1,E. Kalagiakou1, K. Vallianatou1, E. Samaridis1, E. Nikolarou1, P. Pantoula2, G. Erotokritou1, A. Parasi2, K. Sampani3, N. Laoutaris1
• 19th Hellenic Haematology Congress, Athens 19-22 November 2008
  LABORATORY AUTOMATION WITH SYSMEX AUTOMATED HAEMATOLOGIC ANALYSERS & THEIR FUNCTIONS IN CLINICAL PRACTICE
  Nikolaos Laoutaris, Ilias Evmorfiadis
• May 2008: Co-author of the book “The Diabetic Foot”
  Medical Publications G.V. Pasisianou, Scientific Editor-Responsible for the publication: Dr. Dimitrios E. Vogiatzoglou
• 13th Hellenic Internal Medicine Congress, Athens 8th -13th October 2007:
  SYMPTOMATIC HYPOGLYCAEMIA & SELECTIVE SEROTONIN REUPTAKE INHIBITORS
  Dimitrios Papavasiliou1, Vasiliki Dimakopoulou1, Evaggelos Rotas1, Sotirios Georgiou1, Ilias Evmorfiadis1, Evaggelos Neroutsos2, Konstantinos Christopoulos1, Dimitrios Vogiatzoglou1
  1. 1st Pathologic Dept. G. H. Melissia “Amalia Fleming”, 2 Psychiatric Dept. G. H. Elefsina “Thriasio”
• 3rd Hellenic Congress on Wound & Ulcers:
  EXPERIENCE OF 9-YEAR FUNCTION OF DIABETIC FOOT STUDY-THERAPY PRACTICE. PATIENT’S CLINICAL CHARACTERISTICS
  Evmorfiadis I, Volonakis S, Mitsouras K, Renieris I, Vogiatzoglou E, Karagiorgos P,
  Vogiatzoglou D.
• Switch in X-inactivation in a JAK2 V617F-negative case of polycythemia vera with two acquired X-autosome translocations.
  Leukemia Research July 2007 (Vol. 31, Issue 7, Pages 1009-1014)
  K. Manola, C. Stavropoulou, V. Georgakakos, K. Zoi, M. Fisfis, I. Evmorfiadis, C. Zoi, G. Pantelias, K. Stefanoudaki,
  C.Sambani

CONTACT

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Telephone: 210 4809 471